| Literature DB >> 33946300 |
Juan Hoyos1, Tomás Maté2, Juan-Miguel Guerras3,4, Marta Donat5, Cristina Agustí3,6, Matthias Kuske7, Ricardo Fuertes8, Sophocles Chanos9, Francois Pichon10, Luis Sordo1,3, José Pulido1,3, María-José Belza3,5.
Abstract
We analyzed men who have sex with men (MSM) from Denmark, Germany, Greece, Portugal and Spain to identify who would choose HIV self-testing as their preferred testing method and assessed their preferred setting to acquire a self-testing kit and to confirm a reactive result. In 2016, we recruited an online sample of 3725 HIV-negative MSM. We used Poisson regression to identify factors associated with choosing self-testing as the preferred testing option. For those choosing it as their preferred option, we assessed the preferred settings to acquire a self-testing kit and to confirm a reactive result. Not being open about one's sexual behaviors with men was associated with choosing self-testing as the preferred option, except in Greece; older age in Greece and Spain; reporting condomless anal intercourses (CAI) in Germany and Portugal; reporting one previous test in Greece; between 2 and 5 in Spain and with having been tested ≥ 12 months ago in Germany, Portugal and Spain. The internet (32.8%) was the preferred place to acquire a self-testing kit and primary care (34.0%) for confirmation purposes. Self-testing was highly valued, especially among individuals who were not open about their sexual behaviors with men. In certain countries, it was also associated with older age, CAI and being undertested.Entities:
Keywords: HIV; early diagnosis; men who have sex with men; self-testing
Year: 2021 PMID: 33946300 PMCID: PMC8125199 DOI: 10.3390/ijerph18094804
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Sociodemographic profile, outness, sexual behaviors, history of sexually transmitted infections (STI) and testing history.
| Denmark | Germany | Greece | Portugal | Spain | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % |
| % | % | |
|
| |||||||||||
| <25 | 26 | 10.5 | 43 | 5.4 | 61 | 16.8 | 34 | 8.2 | 198 | 10.4 | 8.0 |
| 25–29 | 31 | 12.5 | 85 | 10.7 | 61 | 16.8 | 53 | 12.7 | 314 | 16.5 | 13.0 |
| 30–34 | 30 | 12.1 | 95 | 12.0 | 59 | 16.3 | 65 | 15.6 | 301 | 15.8 | 13.6 |
| 35–39 | 39 | 15.7 | 126 | 15.9 | 78 | 21.5 | 80 | 19.2 | 291 | 15.3 | 16.3 |
| 40–49 | 78 | 31.5 | 227 | 28.6 | 74 | 20.4 | 107 | 25.7 | 505 | 26.5 | 27.3 |
| ≥50 | 44 | 17.7 | 218 | 27.5 | 30 | 8.3 | 78 | 18.7 | 294 | 15.4 | 21.7 |
|
| |||||||||||
| In country of current residence | 212 | 85.8 | 732 | 92.4 | 339 | 97.1 | 360 | 86.7 | 1644 | 87.2 | 90.6 |
| Europe | 22 | 8.9 | 40 | 5.1 | 4 | 1.1 | 14 | 3.4 | 78 | 4.1 | 4.5 |
| Others | 13 | 5.3 | 20 | 2.5 | 6 | 1.7 | 41 | 9.9 | 163 | 8.6 | 4.9 |
|
| |||||||||||
| ≥1,000,000 | 88 | 35.6 | 198 | 25.0 | 201 | 55.7 | 88 | 21.2 | 666 | 35.1 | 30.2 |
| 100,000–999,999 | 84 | 34.0 | 286 | 36.1 | 70 | 19.4 | 145 | 34.9 | 675 | 35.5 | 34.7 |
| 10,000–99,999 | 45 | 18.2 | 213 | 26.9 | 71 | 19.7 | 126 | 30.4 | 406 | 21.4 | 24.7 |
| <10,000 | 30 | 12.1 | 95 | 12.0 | 19 | 5.3 | 56 | 13.5 | 153 | 8.1 | 10.5 |
|
| |||||||||||
| Up to upper secondary education | 100 | 40.5 | 264 | 33.3 | 46 | 12.7 | 113 | 27.2 | 479 | 25.2 | 29.4 |
| Post-secondary non-tertiary education | 10 | 4.0 | 190 | 24.0 | 71 | 19.6 | 27 | 6.5 | 251 | 13.2 | 18.6 |
| University education | 137 | 55.5 | 339 | 42.7 | 246 | 67.8 | 276 | 66.3 | 1170 | 61.6 | 52.0 |
|
| |||||||||||
| Openly | 190 | 76.6 | 428 | 54.0 | 79 | 21.8 | 85 | 20.4 | 907 | 47.7 | 48.6 |
| Discreetly | 43 | 17.3 | 236 | 29.8 | 171 | 47.1 | 227 | 54.4 | 754 | 39.6 | 35.0 |
| Hidden/In total secrecy | 15 | 6.0 | 129 | 16.3 | 113 | 31.1 | 105 | 25.2 | 241 | 12.7 | 16.4 |
|
| |||||||||||
| None | 57 | 23.5 | 288 | 37.1 | 183 | 51.4 | 134 | 33.1 | 688 | 37.0 | 37.3 |
| 1 | 63 | 25.9 | 222 | 28.6 | 116 | 32.6 | 126 | 31.1 | 612 | 32.9 | 30.2 |
| 2–4 | 66 | 27.2 | 170 | 21.9 | 43 | 12.1 | 101 | 24.9 | 372 | 20.0 | 21.1 |
| ≥5 | 57 | 23.5 | 96 | 12.4 | 14 | 3.9 | 44 | 10.9 | 189 | 10.2 | 11.4 |
|
| |||||||||||
| STI diagnosis in the last 12 months | 34 | 14.0 | 72 | 9.4 | 41 | 11.7 | 59 | 14.9 | 203 | 11.0 | 10.5 |
| STI diagnosis > 12 months ago | 100 | 41.2 | 244 | 31.8 | 88 | 25.2 | 112 | 28.2 | 609 | 33.0 | 31.9 |
| No STI diagnosis | 109 | 44.9 | 451 | 58.8 | 220 | 63.0 | 226 | 56.9 | 1031 | 55.9 | 57.6 |
|
| |||||||||||
| 1 | 33 | 13.3 | 133 | 16.8 | 71 | 19.6 | 73 | 17.5 | 358 | 18.8 | 17.5 |
| 2–5 | 93 | 37.5 | 382 | 48.1 | 160 | 44.1 | 189 | 45.3 | 894 | 47.0 | 46.9 |
| 6–9 | 43 | 17.3 | 127 | 16.0 | 54 | 14.9 | 67 | 16.1 | 317 | 16.7 | 16.2 |
| ≥10 | 79 | 31.9 | 152 | 19.1 | 78 | 21.5 | 88 | 21.1 | 334 | 17.6 | 19.4 |
|
| |||||||||||
| ≤3 months ago | 68 | 27.4 | 172 | 21.7 | 147 | 40.5 | 92 | 22.1 | 488 | 25.7 | 24.4 |
| 3–12 months ago | 97 | 39.1 | 299 | 37.8 | 120 | 33.1 | 189 | 45.4 | 733 | 38.6 | 38.2 |
| 1–2 years ago | 46 | 18.5 | 135 | 17.0 | 52 | 14.3 | 60 | 14.4 | 338 | 17.8 | 17.0 |
| > 2 years ago | 37 | 14.9 | 186 | 23.5 | 44 | 12.1 | 75 | 18.0 | 339 | 17.9 | 20.4 |
Proportion of participants who chose self-testing as their preferred testing option (if all available) and associated factors.
| Denmark | Germany | Greece | Portugal | Spain | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| P (%) | PR (95%CI) | P (%) | PR (95%CI) | P (%) | PR (95%CI) | P (%) | PR (95%CI) | P (%) | PR (95%CI) | |
|
| 29.4 | 39.3 | 23.1 | 35.0 | 28.5 | |||||
|
| ||||||||||
| ≥50 | 25.0 | 1.0 (0.4–2.4) | 39.4 | 1.1 (0.7–1.7) | 26.7 | 5.5 (1.6–18.7) | 26.9 | 0.8 (0.4–1.4) | 33.0 | 1.5 (1.1–2.0) |
| 25–49 | 31.5 | 1.3 (0.7–2.8) | 39.6 | 1.1 (0.8–1.8) | 26.8 | 6.0 (2.0–17.7) | 37.4 | 1.2 (0.7–1.9) | 28.6 | 1.3 (1.0–1.7) |
| <25 | 23.1 | 1.0 | 34.9 | 1.0 | 4.9 | 1.0 | 32.4 | 1.0 | 21.7 | 1.0 |
|
| ||||||||||
| Hidden/In total secrecy | 53.3 | 2.0 (1.2–3.4) | 45.7 | 1.4 (1.1–1.8) | 29.2 | 47.6 | 1.6 (1.1–2.3) | 35.7 | 1.3 (1.1–1.6) | |
| Discreetly | 32.6 | 1.2 (0.7–2.0) | 48.3 | 1.5 (1.3–1.8) | 21.1 | 30.8 | 1.0 (0.7–1.5) | 31.3 | 1.2 (1.0–1.4) | |
| Openly | 26.8 | 1.0 | 32.2 | 1.0 | 19.0 | 30.6 | 1.0 | 24.4 | 1.0 | |
|
| ||||||||||
| ≥2 | 33.3 | 48.1 | 1.5 (1.2–1.8) | 14.0 | 40.0 | 1.5 (1.1–2.1) | 30.3 | |||
| 1 | 28.6 | 35.1 | 1.1 (0.9–1.4) | 24.1 | 38.1 | 1.5 (1.0–2.1) | 27.1 | |||
| None | 24.6 | 34.4 | 1.0 | 24.0 | 28.4 | 1.0 | 28.3 | |||
|
| ||||||||||
| 1 | 39.4 | 43.6 | 31.0 | 1.9 (1.2–3.2) | 42.5 | 31.6 | 1.2 (0.9–1.5) | |||
| 2–5 | 23.7 | 40.3 | 23.8 | 1.4 (0.9–2.2) | 36.5 | 30.6 | 1.2 (1.0–1.4) | |||
| >5 | 31.1 | 35.8 | 18.2 | 1.0 | 29.7 | 24.0 | 1.0 | |||
|
| ||||||||||
| >12 months ago | 32.5 | 44.5 | 1.2 (1.0–1.5) | 31.3 | 45.9 | 1.5 (1.1–1.9) | 34.6 | 1.2 (1.1–1.4) | ||
| ≤12 months ago | 27.9 | 35.7 | 1.0 | 20.2 | 29.9 | 1.0 | 25.1 | 1.0 | ||
P: prevalence. PR: adjusted prevalence ratio. 95%CI: 95% confidence interval.
Preferred setting to acquire an HIV self-testing kit and to confirm a reactive result in men who have sex with men who chose self-testing as their preferred testing option.
| Denmark | Germany | Greece | Portugal | Spain | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % |
| % | % | |
|
| |||||||||||
| Through the internet | 31 | 54.4 | 100 | 38.3 | 12 | 17.1 | 24 | 26.7 | 101 | 25.1 | 32.8 |
| It should only be sold in pharmacies | 14 | 24.6 | 52 | 19.9 | 28 | 40.0 | 16 | 17.8 | 137 | 34.1 | 25.5 |
| Supermarkets/drugstores | 4 | 7.0 | 63 | 24.1 | 14 | 20.0 | 25 | 27.8 | 85 | 21.1 | 22.6 |
| Vending machines | 2 | 3.5 | 16 | 6.1 | 10 | 14.3 | 17 | 18.9 | 58 | 14.4 | 9.9 |
| NGO/CBO | 2 | 3.5 | 24 | 9.2 | 0 | 0.0 | 3 | 3.3 | 17 | 4.2 | 6.5 |
| Others | 4 | 7.0 | 6 | 2.3 | 6 | 8.6 | 5 | 5.6 | 4 | 1.0 | 2.7 |
|
| |||||||||||
| Primary care | 36 | 49.3 | 137 | 44.2 | 2 | 2.4 | 24 | 16.6 | 133 | 24.6 | 34.0 |
| Secondary health setting | 11 | 15.1 | 94 | 30.3 | 31 | 36.9 | 35 | 24.1 | 204 | 37.7 | 32.0 |
| Sexual health clinic | 18 | 24.7 | 36 | 11.6 | 30 | 35.7 | 39 | 26.9 | 154 | 28.5 | 19.7 |
| In a NGO/CBO (office or mobile unit) | 8 | 11.0 | 30 | 9.7 | 8 | 9.5 | 38 | 26.2 | 36 | 6.7 | 9.8 |
| Private laboratory | 0 | 0.0 | 7 | 2.3 | 10 | 11.9 | 7 | 4.8 | 10 | 1.8 | 2.9 |
| Others | 0 | 0.0 | 6 | 1.9 | 3 | 3.6 | 2 | 1.4 | 4 | 0.7 | 1.6 |
NGO: non-governmental organization. CBO: community-based organization.